» Articles » PMID: 35493432

Patterns of Indolence in Prostate Cancer (Review)

Overview
Journal Exp Ther Med
Specialty Pathology
Date 2022 May 2
PMID 35493432
Authors
Affiliations
Soon will be listed here.
Abstract

Although prostate cancer is a major cause of cancer-related mortality worldwide, most patients will have a relatively indolent clinical course. Contrary to most other types of cancer, even the diagnosis of locally advanced or metastatic disease is not always lethal. The present review aimed to summarize what is known regarding the underlying mechanisms related to the indolent course of subsets of prostate cancer, at various stages. The data suggested that no specific gene alteration by itself was responsible for carcinogenesis or disease aggressiveness. However, pathway analysis identified genetic aberrations in multiple critical pathways that tend to accumulate over the course of the disease. The progression from indolence into aggressive disease is associated with a complex interplay in which genetic and epigenetic factors are involved. The effect of the immune tumor microenvironment is also very important. Emerging evidence has suggested that the upregulation of pathways related to cellular aging and senescence can identify patients with indolent disease. In addition, a number of tumors enter a long-lasting quiescent state. Further research will determine whether halting tumor evolution is a feasible option, and whether the life of patients can be markedly prolonged by inducing tumor senescence or long-term dormancy.

Citing Articles

eHealth, digital information and technology use of men with prostate cancer.

Jackson S, Yu P, Sowter S, Occhipinti S, Chambers S, Leslie S Digit Health. 2025; 11():20552076241309214.

PMID: 39801580 PMC: 11719434. DOI: 10.1177/20552076241309214.


Unsupervised self-organising map classification of Raman spectra from prostate cell lines uncovers substratified prostate cancer disease states.

West D, Stepney S, Hancock Y Sci Rep. 2025; 15(1):773.

PMID: 39755726 PMC: 11700215. DOI: 10.1038/s41598-024-83708-6.


MicroRNA in prostate cancer: from biogenesis to applicative potential.

Luo X, Wen W BMC Urol. 2024; 24(1):244.

PMID: 39506720 PMC: 11539483. DOI: 10.1186/s12894-024-01634-1.


The Risk Factors and Screening Uptake for Prostate Cancer: A Scoping Review.

Mumuni S, ODonnell C, Doody O Healthcare (Basel). 2023; 11(20).

PMID: 37893854 PMC: 10606491. DOI: 10.3390/healthcare11202780.


Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients.

Giesen A, Baekelandt L, Devlies W, Devos G, Dumez H, Everaerts W Front Oncol. 2023; 13:1265812.

PMID: 37810962 PMC: 10551452. DOI: 10.3389/fonc.2023.1265812.


References
1.
Jung S, Hwang H, Kang D, Park H, Lee H, Jeong D . mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53. Oncogene. 2018; 38(10):1639-1650. PMC: 6755978. DOI: 10.1038/s41388-018-0521-8. View

2.
Lopez-Dominguez J, Rodriguez-Lopez S, Ahumada-Castro U, Desprez P, Konovalenko M, Laberge R . transcript variant 2 is a marker of aging and cellular senescence. Aging (Albany NY). 2021; 13(10):13380-13392. PMC: 8202863. DOI: 10.18632/aging.203110. View

3.
Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

4.
Irshad S, Bansal M, Castillo-Martin M, Zheng T, Aytes A, Wenske S . A molecular signature predictive of indolent prostate cancer. Sci Transl Med. 2013; 5(202):202ra122. PMC: 3943244. DOI: 10.1126/scitranslmed.3006408. View

5.
Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View